Overview 2020-01-23T13:25:48+00:00

Midlands and Wales Advanced Therapy Treatment Centre

The Midlands and Wales Advanced Therapy Treatment Centre (MW-ATTC) consists of a large regional network with the necessary commercial and NHS infrastructure required to facilitate the delivery of advanced therapy treatments to patients. The centre includes a wide range of specialists in advanced therapy manufacturing including academic and commercial partners, logistics companies, specialists in clinical trial delivery and teams focussed on IT solutions and health economics.

The MW-ATTC is looking to

  • Overcome the current challenges to trial recruitment to cell therapy trials by developing an empowered trials network. Building on the success of the national Haemato-oncology Trials Acceleration Programme (TAP), we will establish a trials hub and build new capacity and skills across our hospital network. This will enable us to rapidly deliver cell therapy trials
  • Establish best practice for the safe and effective delivery of ATMPs to patients by creating standardised SOPs and delivering training to staff across the hospitals network
  • Define best practice for ATMP near-patient preparation and therapy delivery by training hospital pharmacists, clinicians and technical personnel
  •  Set up robust connected supply chains for manufacture and delivery of ATMPs, including comprehensive data collection and analysis, leveraging the proven capabilities of our commercial partners
  • Develop and deliver comprehensive data systems that track and trace all samples and ATMPs, both along the manufacturing supply chain and within hospitals
  • Ensure best practice for patient follow-up and subsequent data capture. This will be critical for health-economic analysis, for verification of efficacy, and subsequently steer future prescription and clinical decisions

Location

The MW-ATTC covers the Midlands and Wales, with clinical sites based in Birmingham, Cardiff, Nottingham and Swansea.

Leadership team

Prof Philip Newsome PhD, FRCPE
Prof Philip Newsome PhD, FRCPE
MW-ATTC Director

Director of Centre for Liver & Gastrointestinal Research
Deputy Director of NIHR Birmingham BRC
Professor of Hepatology & Consultant Hepatologist

Dr Mark Briggs
Dr Mark Briggs
Welsh Blood Service

Deputy Director

Nisha Sungum
Nisha Sungum
MW-ATTC Programme Manager

University Hospitals Birmingham NHS Foundation Trust

Our partners

University Hospitals Birmingham NHS Foundation Trust

University Hospitals Birmingham NHS Foundation Trust

University Hospitals Birmingham NHS Foundation Trust (UHB) is one of the highest performing healthcare organisations in Europe with a proven international reputation for its quality of care, information technology, clinical education and training and research.

UHB is a regional centre for cancer, has the second largest renal dialysis programme in the UK and has the largest solid organ transplantation programme in Europe. It also provides a series of highly specialist cardiac and liver services and is a major specialist centre for burns and plastic surgery. The Trust is also a regional Neuroscience and Major Trauma Centre and is world-renowned for its trauma care. The Trust employs more than 9,000 staff and runs the largest single site hospital in the country.

Nisha Sungum
MW-ATTC Programme Manager
www.uhb.nhs.uk

University of Birmingham

The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, teachers and more than 5,000 international students from over 150 countries.

Dr Parini Mankad
Rheumatology Research Group Manager
www.birmingham.ac.uk

Welsh Blood Service (Velindre University NHS Trust)

Velindre University NHS Trust provides specialist cancer and blood services across South and Mid Wales through Velindre Cancer Centre and the Welsh Blood Service.  Delivering quality, care and excellence to our patients and donors is at the heart of our organisation. The Welsh Blood Service collects voluntary, non-remunerated blood donations from the general public. The Velindre Cancer Centre provides specialist cancer services to over 1.5 million people in South East Wales and beyond. Additionally, Velindre University NHS Trust is ‘Host’ to a number of external organisations: NHS Wales Informatics Service (NWIS), NHS Wales Shared Services Partnership and Health Technology Wales (HTW).

Dr Mark Briggs
Head of Cell and Gene Therapy
www.welshblood.org.uk

Nottingham University Hospitals

Nottingham University Hospitals NHS Trust

Nottingham University Hospitals NHS Trust is one of the biggest and busiest acute hospitals in England, employing over 16,000 staff. We provide care to over 2.5million residents of Nottingham and its surrounding communities and specialist services to a further 3-4million people from neighbouring counties.

We have national and international reputations for specialist services such as stroke, renal, spinal, breast, neurosciences, cancer services and trauma.

We are one of the most research-active Trusts in the country with world-leading clinical research delivered across our hospitals and through our NIHR Nottingham Biomedical Research Centre which is translating research discoveries into new treatments for common diseases including asthma and arthritis. Central to our research is our expertise in Magnetic Resonance Imaging.

Prof Poulam Patel
Professor of Clinical Oncology
www.nuh.nhs.uk

NHS Blood and Transplant

NHS Blood and Transplant

NHSBT provide a blood and transplantation service to the NHS, looking after blood donation services in England and transplant services across the UK. This includes managing the donation, storage and transplantation of blood, organs, tissues, bone marrow and stem cells, and researching new treatments and processes.

Our Cellular and Molecular Therapies facilities provide a comprehensive range of services to support haemopoietic stem cell transplantation and offer a range of established and innovative cell therapies for the treatment of inherited and acquired haematological disorders. Our Clinical Biotechnology Centre manufactures DNA-based therapeutics for clinical application.

Dr Ceri Roberts
Scientific Training Manager – Cellular and Molecular Therapies
www.nhsbt.nhs.uk

Asymptote GE

Asymptote combines world leading research into the science of cell freezing with engineering expertise to create pioneering cryochain technology for advanced medicines. Our portfolio of innovative products preserves cell viability during cryogenic processing of cellular therapies – from freezing to thawing – to support our customers’ work to improve healthcare throughout the world.

Dr Bill Shingleton
Alliances Manager
www.asymptote.co.uk

Thermo Fisher Scientific

The success of a cell therapy clinical trial rests on the ability to deliver a viable, potent product – the direct result attributable to the strategy. Thermo Fisher Scientific is positioned with resources and global expertise to support customers on the path towards commercialization. Our global infrastructure enables customers to conduct clinical trials across multiple geographies while providing patients with access to life changing therapies. Cryogenic storage and logistics allow us to configure each site to meet specific requirements of individual clinical trial. We can help navigate many of the unforeseen challenges associated with cell therapy clinical development and commercialization.

Richard Bazell
Senior Project Manager
www.fisherbioservices.com/celltherapy

Rexgenero

Rexgenero is a late-stage regenerative medicine company developing advanced cell-based therapeutics for the treatment of critical limb ischemia (CLI), a large global market with high unmet medical need.

Dr Edwin Wagena
Chief Operating Officer
www.rexgenero.com

Immetacyte

IMMETACYTE is a clinical-stage immuno-oncology company with an established, profitable GMP CDMO business for advanced cell therapies. Immetacyte’s patient-specific immunotherapy uses T-cells isolated from the patient’s tumour that are cancer specific and have been shown to home to the tumour and attack it – Tumour-Infiltrating Lymphocytes (TIL). The power of this truly specific TIL cell therapy against solid tumours was recognised by Immetacyte some years ago.

Our therapy is now clinically validated. Immetacyte has used TIL successfully to treat metastatic melanoma patients, some of whom have failed all other treatments (including checkpoint inhibitors). We have demonstrated that our therapy produces major tumour responses in 50% of patients and durable remissions and potential cures in around 20%.

We have built upon the expertise of researchers who have successfully undertaken scientific and clinical research alongside Professor Robert Hawkins. Professor Hawkins is a leader in the field having undertaken several complex research projects and clinical trials involving: TIL, CAR-T, TCR based T cell therapies, cell selection, gene therapy, expansion of patient derived cells.

Our clinical data act as a cornerstone for us to enter into a pivotal clinical trial in this indication. Having successfully treated melanoma we will move onto other solid tumour indications and next generation TIL-based products to build a pipeline of TIL-based therapies

Dr Ryan Guest
Director of Cell Production
www.cellulartherapeutics.co.uk

Orbsen Therapeutics

Orbsen Therapeutics

Orbsen Therapeutics is a regenerative medicine company based in Galway, Ireland.
Using proprietary technology, we are developing ground-breaking stromal cell treatments to address some of today’s most challenging diseases.

Stromal cells hold great promise as an alternative to drugs and surgical procedures for treating a wide range of medical conditions including heart disease, arterial disease of the limbs, diabetes complications, arthritis and other inflammatory conditions. The treatment potential is linked to the cells’ natural capacity to dampen inflammation and promote healing, repair and regeneration of damaged tissues.

Orbsen has discovered and patented a unique method for purifying these rare, therapeutic cells and developing them for clinical use. The cells can be selected from a single donor, expanded and frozen to generate many doses of a high-margin, “off-the-shelf” therapeutic product.

Dr Stephen Elliman
Chief Scientific Officer
https://orbsentherapeutics.com/

TrakCel

TrakCel is a cloud-based Cellular Orchestration Platform (COP) that enables the streamlined delivery of advanced therapies to patients. The platform can be configured to processes defined by the cell therapy manufacturer and records all critical data across the supply chain in a FDA 21 CFR Part 11 and EU Annex 11 compliant manner.

TrakCel is a software platform that delivers:

  • End-to-end Chain of Identity (COI) management
  • Full collection to administration visibility and Chain of Custody (COC) reporting
  • Automated scheduling of activities between patient facing clinical and manufacturing sites
  • Integration capabilities with ERP, CRM, and other similar systems
  • Workflow-driven consistent processing
  • Role-based functionality and information access for physicians, nurses, & supply chain partners
  • Cloud hosted multilingual platform

Dr Matthew Lakelin
VP Business Development and Scientific
www.trakcel.com

World Courier

World Courier is a global specialty logistics company that designs world-class logistics and supply chain programmes in complete alignment with our customers’ business goals. Pharmaceutical companies rely on us because they value the peace of mind that comes with our unsurpassed knowledge, global reach and flawless supply chain execution. Each trusted partnership we form with a customer is deeply rooted in our shared vision of improving global health. With 2,000+ associates in more than 140 offices across the globe, we offer solutions that instil confidence in the on-time, on-temperature delivery of critical products. When trust is absolutely essential, there’s only one choice: World Courier.

Simon Ellison
Cell and Gene Therapy Service Director
www.worldcourier.com

Miltenyi Biotec

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Today, Miltenyi Biotec has 2,500 employees in 28 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.

Michele Giroux
Country Manager UK &Ireland
www.miltenyibiotec.com

Birmingham Health Partners

Birmingham Health Partners is a strategic alliance between the NHS and University of Birmingham, which sits at the centre of a regional population of over five million people. Accelerating patient access to new, innovative medicines and technologies is at the heart of what the organisation does.
Excellent academics and clinicians working together, along with a very large and diverse catchment area, give Birmingham and the broader West Midlands a comparative advantage in translational research, in particular clinical trialling.

University Hospitals of Leicester NHS Trust

University Hospitals of Leicester NHS Trust is one of the biggest and busiest NHS trusts in the country, employing over 15,000 staff and serving the one million residents of Leicester, Leicestershire and Rutland.

We pave the way for future treatments and care pathways through pioneering research for the benefit of all patients – from the youngest to the oldest. Our nationally and internationally-renowned research in cardiovascular and respiratory diseases, diabetes, cancer and renal disorders has a proven track record of making a real difference to patients’ lives through new medicines, innovative devices and techniques, clinical education and changes to best practice guidelines.

Visit our other centres